Thrombin mutant W215A/E217A acts as a platelet GPIb antagonist

Michelle A. Berny, Tara C. White, Erik Tucker, Leslie A. Bush-Pelc, Enrico Di Cera, Andras Gruber, Owen McCarty

Research output: Contribution to journalArticle

32 Scopus citations


OBJECTIVE - Thrombin containing the mutations Trp215Ala and Glu217Ala (WE) selectively activates protein C and has potent antithrombotic effects in primates. The aim of this study was to delineate the molecular mechanism of direct WE-platelet interactions under static and shear conditions. METHODS AND RESULTS - Purified platelets under static conditions bound and spread on immobilized wild-type but not WE thrombin. In PPACK-anticoagulated blood under shear flow conditions, platelets tethered and rolled on both wild-type and WE thrombin, and these interactions were abrogated by the presence of a glycoprotein Ib (GPIb)-blocking antibody. Platelet deposition on collagen was blocked in the presence of WE, but not wild-type thrombin or prothrombin. WE also abrogated platelet tethering and rolling on immobilized von Willebrand factor in whole blood under shear flow. CONCLUSIONS - These observations demonstrate that the thrombin mutant WE, while not activating platelets, retains the ability to interact with platelets through GPIb, and inhibits GPIb-dependent binding to von Willebrand factor-collagen under shear.

Original languageEnglish (US)
Pages (from-to)329-334
Number of pages6
JournalArteriosclerosis, Thrombosis, and Vascular Biology
Issue number2
Publication statusPublished - Feb 2008



  • GPIb
  • Platelet
  • Thrombin
  • Von Willebrand factor

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this